Spontaneous long-term smoking cessation in a patient with schizophrenia after treatment with ziprasidone

Addictive Disorders and their Treatment

Volumn 3, Issue 3, 2004, Pages 138-143

  Vartian, Brian A ^a   Hawken, Emily R ^a   Delva, Nicholas J ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b NONE   (Canada)

Author keywords

Nicotine; Schizophrenia; Smoking cessation; Ziprasidone

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; CHLORPROMAZINE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; NEUROLEPTIC AGENT; ZIPRASIDONE;

ADULT; ARTICLE; CASE REPORT; HUMAN; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING CESSATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 4444243428     PISSN: 15315754     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.adt.0000129084.99647.20     Document Type: Article

References (51)

1. Spring B, Pingitore R, McChargue DE. Reward value of cigarette smoking for comparably heavy smoking schizophrenic, depressed, and nonpatient smokers. Am J Psychiatry. 2003;160:316-322.
2. McEvoy JP, Freudenreich O, Levin ED, et al. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology (Berl). 1995;119:124-126.
3. McEvoy JP, Freudenreich O, Wilson WH. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry. 1999;46:125-129.
4. McEvoy JP, Brown S. Smoking in first-episode patients with schizophrenia. [Letter] Am J Psychiatry. 1999;156:1120-1121.
5. Lyon ER. A review of the effects of nicotine on schizophrenia and antipsychotic medications. Psychiatr Serv. 1999;50:1346-1350.
6. George TP, Sernyak MJ, Ziedonis DM, et al. Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry. 1995;56:344-346.
7. George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000;157:1835-1842.
8. Procyshyn RM, Ihsan N, Thompson D. A comparison of smoking behaviors between patients treated with clozapine and depot neuroleptics. Int Clin Psychopharmacol. 2001;16:291-294.
9. Kay SR, Fiszbean A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizopbr Bull. 1987;13:261-276.
10. Owen F, Simpson MDC. The neurochemistry of schizophrenia. In: Hirsch SR, Weinberger DR, eds. Schizophrenia. Cambridge, Mass.: Blackwell Science; 1995:358-378.
11. Seeman P, Chau-Wong M, Tedesco J, et al. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci. 1975;72:4376-4380.
12. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976;192:481-483.
13. Ananth J, Burgoyne KS, Gadasalli R, et al. How do the atypical antipsychotics work? J Psychiatry Neurosci. 2001;26:385-394.
14. Kasper S, Tauscher J, Küfferle B, et al. Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 1999;249(Suppl 4):83-89.
15. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol. 2002;67:53-83.
16. Szekeres G, Pavics L, Janka Z. Investigation of the dopamine dysregulation hypothesis of schizophrenia with neuroimaging techniques. Ideggyogy Sz. 2002;55:226-232.
17. Wilkins JN. Pharmacotherapy of schizophrenia patients with comorbid substance abuse. Schizophr Bull. 1997;23:215-228.
18. Carlsson A, Waters N, Holm-Waters S, et al. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol. 2001;41:237-260.
19. Meltzer HY, Sumiyoshi T. Atypical antipsychotic drugs improve cognition in schizophrenia. Biol Psychiatry. 2003;53:265-267.
20. Westerink BHC. Can antipsychotic drugs be classified by their effects on a particular group of dopamine neurons in the brain? Eur J Pharmacol. 2002;455:1-18.
21. Sziráki I, Sershen H, Hashim A, et al. Receptors in the ventral tegmental area mediating nicotine-induced dopamine release in the nucleus accumbens. Neurochem Res. 2002;27:253-261.
22. Due DL, Huettel SA, Hall WG, et al. Activation in mesolimbic and visuospatial neural circuits elicited by smoking cues: evidence from functional magnetic resonance imaging. Am J Psychiatry. 2002;159:954-960.
23. Nisell M, Nomikos GG, Hertel P, et al. Condition-independent sensitization of locomotor stimulation and mesocortical dopamine release following chronic nicotine treatment in the rat. Synapse. 1996;22:369-381.
24. Srinivasan TN, Thara R. Smoking in schizophrenia - all is not biological. Schizophr Res. 2002;56:67-74.
25. Le Houezec J, Benowitz NL. Basic and clinical psychopharmacology of nicotine. Clin Chest Med. 1991;12:681-699.
26. Stolerman IP, Mirza NR, Shoaib M. Nicotine psychopharmacology: addiction, cognition, and neuroadaptation. Med Res Rev. 1995;15:47-72.
27. Carboni E, Bortone L, Giua C, et al. Dissociation of physical abstinence signs from changes in extracellular dopamine in the nucleus accumbens and in the prefrontal cortex of nicotine dependent rats. Drug Alcohol Depend. 2000;58:93-102.
28. Raedler TJ, Knable MB, Jones DW, et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry. 2003;160:118-127.
29. Hartman DS, Lanau F. Diversity of dopamine receptors: new molecular and pharmacological developments. Pol J Pharmacol. 1997;49:191-199.
30. George TP, Verrico CD, Picciotto MR, et al. Nicotinic modulation of mesoprefrontal dopamine neurons: pharmacologic and neuroanatomic characterization. J Pharmacol Exp Ther. 2000;295:58-66.
31. George TP, Vessicchio JC, Termine A, et al. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology. 2002;26:75-85.
32. Strange PG. Mechanisms of action of anti-psychotic drugs. Biochem Soc Trans. 1999;27:175-178.
33. Li Z, Ichikawa J, Meltzer HY. A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens. Psychopharmacology (Berl). 2003;167:315-323.
34. Heidbreder CA, Foxton R, Cilia J, et al. Increased responsiveness of dopamine to atypical, but not typical antipsychotics in the medial prefrontal cortex of rats reared in isolation. Psychopharmacology (Berl). 2001;156:338-351.
35. Adler LE, Hoffer LD, Wiser A, et al. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry. 1993;150:1856-1861.
36. Goff DC, Henderson DC, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry. 1992;149:1189-1194.
37. Dawe S, Gerada C, Russell MAH, et al. Nicotine intake in smokers increases following a single dose of haloperidol. Psychopharmacology (Berl). 1995;117:110-115.
38. Glynn SM, Sussman S. Why patients smoke. Hosp Commun Psychiatry. 1990;41:1027-1028.
39. Carpenter WT, Gold JM. Another view of therapy for cognition in schizophrenia. Biol Psychiatry. 2002;52:969-971.
40. Meltzer HY. Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci. 1995;3:64-75.
41. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl). 1989;99:S18-S27.
42. 2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res. 2002;947:157-165.
43. 1A receptor agonism. Brain Res. 2002;956:349-357.
44. Ichikawa J, Dai J, O'Laughlin IA, et al. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology. 2002;26:325-339.
45. Netter P, Toll C, Lujic C, et al. Addictive and nonaddictive smoking as related to responsivity to neurotransmitter systems. Behav Pharmacol. 2002;13:441-449.
46. Malone KM, Waternaux C, Haas GL, et al. Cigarette smoking, suicidal behavior, and serotonin function in major psychiatric disorders. Am J Psychiatry. 2003;160:773-779.
47. Benwell ME, Balfour DJK. Effects of nicotine administration and its withdrawal on plasma corticosterone and brain 5-hydroxyindoles. Psychopharmacology (Berl). 1979;63:7-11.
48. Rosecrans JA. The psychopharmacological basis of nicotine's differential effects on behavior: individual subject variability in the rat. Behav Genet. 1995;25:187-196.
49. Levin ED, Simon BB. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl). 1998;138:217-230.
50. Adler LE, Olincy A, Waldo M, et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull. 1998;24:189-202.
51. George TP, Vessicchio JC, Termine A, et al. A placebo controlled trial of buproprion for smoking cessation in schizophrenia. Biol Psychiatry. 2002;52:53-61.